Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Amyloidosis Therapeutics Industry: Supply and Demand, Markets and Prices 2021-2027

Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Amyloidosis Therapeutics Market Status and Forecast (2016-2027)
      • 1.3.2 Global Amyloidosis Therapeutics Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Amyloidosis Therapeutics Supply by Company

    • 2.1 Global Amyloidosis Therapeutics Sales Volume by Company
    • 2.2 Global Amyloidosis Therapeutics Sales Value by Company
    • 2.3 Global Amyloidosis Therapeutics Price by Company
    • 2.4 Amyloidosis Therapeutics Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Amyloidosis Therapeutics Market Status by Category

    • 3.1 Amyloidosis Therapeutics Category Introduction
      • 3.1.1 AG-10
      • 3.1.2 ALN-ANG
      • 3.1.3 ALN-TTRsc02
      • 3.1.4 CAEL-101
      • 3.1.5 Canakinumab
      • 3.1.6 Others
    • 3.2 Global Amyloidosis Therapeutics Market by Category
      • 3.2.1 Global Amyloidosis Therapeutics Sales Volume by Category (2016-2021)
      • 3.2.2 Global Amyloidosis Therapeutics Sales Value by Category (2016-2021)
      • 3.2.3 Global Amyloidosis Therapeutics Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Amyloidosis Therapeutics Market Status by End User/Segment

    • 4.1 Amyloidosis Therapeutics Segment by End User/Segment
      • 4.1.1 AL Amyloidosis
      • 4.1.2 AA Amyloidoses
      • 4.1.3 ATTR Amyloidoses
      • 4.1.4 Others
    • 4.2 Global Amyloidosis Therapeutics Market by End User/Segment
      • 4.2.1 Global Amyloidosis Therapeutics Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Amyloidosis Therapeutics Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Amyloidosis Therapeutics Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Amyloidosis Therapeutics Market Status by Region

    • 5.1 Global Amyloidosis Therapeutics Market by Region
      • 5.1.1 Global Amyloidosis Therapeutics Sales Volume by Region
      • 5.1.2 Global Amyloidosis Therapeutics Sales Value by Region
    • 5.2 North America Amyloidosis Therapeutics Market Status
    • 5.3 Europe Amyloidosis Therapeutics Market Status
    • 5.4 Asia Pacific Amyloidosis Therapeutics Market Status
    • 5.5 Central & South America Amyloidosis Therapeutics Market Status
    • 5.6 Middle East & Africa Amyloidosis Therapeutics Market Status

    6 North America Amyloidosis Therapeutics Market Status

    • 6.1 North America Amyloidosis Therapeutics Market by Country
      • 6.1.1 North America Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
      • 6.1.2 North America Amyloidosis Therapeutics Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Amyloidosis Therapeutics Market Status

    • 7.1 Europe Amyloidosis Therapeutics Market by Country
      • 7.1.1 Europe Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Amyloidosis Therapeutics Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Amyloidosis Therapeutics Market Status

    • 8.1 Asia Pacific Amyloidosis Therapeutics Market by Country
      • 8.1.1 Asia Pacific Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Amyloidosis Therapeutics Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Amyloidosis Therapeutics Market Status

    • 9.1 Central & South America Amyloidosis Therapeutics Market by Country
      • 9.1.1 Central & South America Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Amyloidosis Therapeutics Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Amyloidosis Therapeutics Market Status

    • 10.1 Middle East & Africa Amyloidosis Therapeutics Market by Country
      • 10.1.1 Middle East & Africa Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Amyloidosis Therapeutics Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Amyloidosis Therapeutics Manufacturing Cost Analysis
    • 11.5 Amyloidosis Therapeutics Sales Channel and Distributors Analysis
      • 11.5.1 Amyloidosis Therapeutics Sales Channel
      • 11.5.2 Amyloidosis Therapeutics Distributors
    • 11.6 Amyloidosis Therapeutics Downstream Major Buyers

    12 Global Amyloidosis Therapeutics Market Forecast by Category and by End User/Segment

    • 12.1 Global Amyloidosis Therapeutics Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Amyloidosis Therapeutics Forecast by Category
      • 12.2.1 Global Amyloidosis Therapeutics Sales Volume Forecast by Category
      • 12.2.2 Global Amyloidosis Therapeutics Sales Value Forecast by Category
      • 12.2.3 Global Amyloidosis Therapeutics Price Forecast by Category
    • 12.3 Global Amyloidosis Therapeutics Forecast by End User/Segment
      • 12.3.1 Global Amyloidosis Therapeutics Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Amyloidosis Therapeutics Sales Value Forecast by End User/Segment
      • 12.3.3 Global Amyloidosis Therapeutics Price Forecast by End User/Segment

    13 Global Amyloidosis Therapeutics Market Forecast by Region/Country

    • 13.1 Global Amyloidosis Therapeutics Market Forecast by Region (2022-2027)
      • 13.1.1 Global Amyloidosis Therapeutics Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Amyloidosis Therapeutics Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 SOM Innovation Biotech SL
      • 14.1.1 Company Information
      • 14.1.2 Amyloidosis Therapeutics Product Introduction
      • 14.1.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Prothena Corporation Plc
      • 14.2.1 Company Information
      • 14.2.2 Amyloidosis Therapeutics Product Introduction
      • 14.2.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 ProteoTech, Inc.
      • 14.3.1 Company Information
      • 14.3.2 Amyloidosis Therapeutics Product Introduction
      • 14.3.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Pfizer Inc.
      • 14.4.1 Company Information
      • 14.4.2 Amyloidosis Therapeutics Product Introduction
      • 14.4.3 Pfizer Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Onyx Pharmaceuticals, Inc.
      • 14.5.1 Company Information
      • 14.5.2 Amyloidosis Therapeutics Product Introduction
      • 14.5.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Millennium Pharmaceuticals, Inc.
      • 14.6.1 Company Information
      • 14.6.2 Amyloidosis Therapeutics Product Introduction
      • 14.6.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Isis Pharmaceuticals, Inc.
      • 14.7.1 Company Information
      • 14.7.2 Amyloidosis Therapeutics Product Introduction
      • 14.7.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 GlaxoSmithKline Plc
      • 14.8.1 Company Information
      • 14.8.2 Amyloidosis Therapeutics Product Introduction
      • 14.8.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Celgene Corporation
      • 14.9.1 Company Information
      • 14.9.2 Amyloidosis Therapeutics Product Introduction
      • 14.9.3 Celgene Corporation Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Bsim2
      • 14.10.1 Company Information
      • 14.10.2 Amyloidosis Therapeutics Product Introduction
      • 14.10.3 Bsim2 Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Bellus Health Inc.
    • 14.12 Arcturus Therapeutics, Inc
    • 14.13 Alnylam Pharmaceuticals, Inc.

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Amyloidosis Therapeutics market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Amyloidosis Therapeutics market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      AG-10
      ALN-ANG
      ALN-TTRsc02
      CAEL-101
      Canakinumab
      Others

      Segmented by End User/Segment
      AL Amyloidosis
      AA Amyloidoses
      ATTR Amyloidoses
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      SOM Innovation Biotech SL
      Prothena Corporation Plc
      ProteoTech, Inc.
      Pfizer Inc.
      Onyx Pharmaceuticals, Inc.
      Millennium Pharmaceuticals, Inc.
      Isis Pharmaceuticals, Inc.
      GlaxoSmithKline Plc
      Celgene Corporation
      Bsim2
      Bellus Health Inc.
      Arcturus Therapeutics, Inc
      Alnylam Pharmaceuticals, Inc.

      Buy now